Advertisement

Topics

Fibrinogen Deficiency (Factor I Deficiency) - Pipeline Review, H1 2015

01:13 EDT 15 Apr 2015 | BioPortfolio Reports

Recently added to the BioPortfolio report store, Fibrinogen Deficiency (Factor I Deficiency) - Pipeline Review, H1 2015 is a new report from Global Markets Direct published on 2015-03-10. This 38-page report is available in PDF from $2000.

Fibrinogen Deficiency (Factor I Deficiency) - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Fibrinogen Deficiency (Factor I Deficiency) - Pipeline Review, H1 2015’, provides an overview of the Fibrinogen Deficiency (Factor I Deficiency)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Fibrinogen Deficiency (Factor I Deficiency), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fibrinogen Deficiency (Factor I Deficiency) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Fibrinogen Deficiency (Factor I Deficiency)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Fibrinogen Deficiency (Factor I Deficiency) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Fibrinogen Deficiency (Factor I Deficiency) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Fibrinogen Deficiency (Factor I Deficiency) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Fibrinogen Deficiency (Factor I Deficiency) Overview 6
Therapeutics Development 7
Pipeline Products for Fibrinogen Deficiency (Factor I Deficiency) - Overview 7
Pipeline Products for Fibrinogen Deficiency (Factor I Deficiency) - Comparative Analysis 8
Fibrinogen Deficiency (Factor I Deficiency) - Therapeutics under Development by Companies 9
Fibrinogen Deficiency (Factor I Deficiency) - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Fibrinogen Deficiency (Factor I Deficiency) - Products under Development by Companies 12
Fibrinogen Deficiency (Factor I Deficiency) - Companies Involved in Therapeutics Development 13
Biotest AG 13
China Biologic Products, Inc. 14
Grifols, S.A. 15
Octapharma AG 16
Fibrinogen Deficiency (Factor I Deficiency) - Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Target 18
Assessment by Mechanism of Action 19
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Drug Profiles 24
fibrinogen - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
fibrinogen concentrate (human) - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
fibrinogen concentrate (human) - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
fibrinogen concentrate (human) - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
fibrinogen concentrate (human) - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Fibrinogen Deficiency (Factor I Deficiency) - Recent Pipeline Updates 29
Fibrinogen Deficiency (Factor I Deficiency) - Discontinued Products 30
Fibrinogen Deficiency (Factor I Deficiency) - Product Development Milestones 31
Featured News & Press Releases 31
Dec 19, 2012: CSL Behring's Fibrinogen Concentrate Given As First-Line Therapy Safely Reduces Need For Transfusion After Aortic Surgery In Phase II Study 31
Mar 23, 2012: China Biologic Receives SFDA Approval To Begin Clinical Trials For Human Fibrinogen 32
Mar 11, 2009: CSL Behring Receives Orphan-Drug Exclusivity for RiaSTAP 32
Mar 11, 2009: CSL Behring Receives Orphan-Drug Exclusivity for RiaSTAP 33
Jan 16, 2009: CSL Behring Receives FDA Approval of RiaSTAP, First and Only Approved Treatment of Acute Bleeding Episodes in Patients with Congenital Fibrinogen Deficiency 34
Jan 16, 2009: CSL Behring Receives FDA Approval of RiaSTAP, First and Only Approved Treatment of Acute Bleeding Episodes in Patients with Congenital Fibrinogen Deficiency 34
Jul 21, 2008: CSL Behring Submits BLA Requesting Approval of Human Fibrinogen Concentrate for the Treatment of Congenital Bleeding 35
Jul 21, 2008: CSL Behring Submits BLA Requesting Approval of Human Fibrinogen Concentrate for the Treatment of Congenital Bleeding 36
Jul 21, 2008: CSL Behring Submits BLA…

For more information open Fibrinogen Deficiency (Factor I Deficiency) - Pipeline Review, H1 2015.

SKU: GMDHC6341IDB

Original Article: Fibrinogen Deficiency (Factor I Deficiency) - Pipeline Review, H1 2015

NEXT ARTICLE

More From BioPortfolio on "Fibrinogen Deficiency (Factor I Deficiency) - Pipeline Review, H1 2015"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...